CSL shareholders revolt against executive pay packages
Australian biotech giant CSL faces investor fury as shareholders overwhelmingly vote against executive pay, though board members narrowly survive removal votes amid share price concerns.
Australian biotech giant CSL faces investor fury as shareholders overwhelmingly vote against executive pay, though board members narrowly survive removal votes amid share price concerns.